Acucela Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, AMD, Stargardt disease, cataract and presbyopia. The company is also developing a monitoring device for neovascular retinal diseases, to be used directly by patients. http://www.acucela.com; http://www.kubotaholdings.co.jp/en/
Company Details
- Employees
- 25
- Founded
- -
- Address
- 818 Stewart Street,
- Phone
- (425)527-3260
- pr****@****ela.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- acucela.com
- Keywords
- Ophthalmology.
- HQ
- Seattle, WA
Acucela Inc. Questions
Acucela Inc.'s helpline number is (425)527-3260
Acucela Inc.'s website is acucela.com
Acucela Inc.'s LinkedIn profile is https://www.linkedin.com/company/acucela-inc.
Acucela Inc. has
25 employees.
View email and phone details for 25
employees at Acucela Inc..
Acucela Inc.'s industry is
Biotechnology Research
Acucela Inc.'s top competitors are
Regeneron,
Eyenovia, Inc.,
Editas Medicine,
Sight Sciences,
Alkeus Pharmaceuticals, Inc.,
Denali Therapeutics,
Kodiak Sciences,
Gilead Sciences,
Sarepta Therapeutics,
Eikon Therapeutics.
Acucela Inc.'s support email address is pr@acucela.com
Acucela Inc.'s categories are Biotechnology Research
Acucela Inc.'s founding year is 2002
